Related Experiment Video

Updated: May 20, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Antitumor activity of novel chimeric peptides derived from cyclinD/CDK4 and the protein transduction domain 4

Haili Wang1, Xi Chen, Yanping Chen

  • 1Department of Bioengineering, Zhengzhou University, 100 Science Road, Zhengzhou 450001, China.

Amino Acids
|July 18, 2012
PubMed

Insights

Novel chimeric peptides targeting cyclinD/CDK4 complexes show potent anticancer activity by inhibiting cell proliferation and inducing apoptosis. These PTD4-conjugated peptides offer a promising new avenue for cancer therapy with minimal side effects.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • CyclinD/CDK4 complexes are crucial regulators of cell cycle progression.
  • Dysregulation of these complexes is implicated in various cancers, making them attractive therapeutic targets.

Purpose of the Study:

  • To design and synthesize novel chimeric peptides targeting CyclinD1/CDK4 and CyclinD3/CDK4 complexes.
  • To evaluate the anti-proliferative and anti-tumor effects of these peptides in cancer models.

Main Methods:

  • Selection of key peptide motifs from CyclinD1/CDK4 and CyclinD3/CDK4 complexes.
  • Conjugation of selected peptides to protein transduction domain 4 (PTD4) to create chimeric peptides (PTD4-D1, PTD4-D3, PTD4-K4).
  • In vitro assessment of anti-proliferation effects on cancer cell lines and in vivo tumor challenge experiments.

Main Results:

  • The synthesized chimeric peptides (PTD4-D1, PTD4-D3, PTD4-K4) demonstrated significant anti-proliferation effects.
  • These peptides effectively competed with cyclinD/CDK4 complexes, inducing G1/S phase arrest and apoptosis in cancer cells.
  • In vivo studies revealed potent anti-tumor activity with no significant observed side effects.

Conclusions:

  • The developed chimeric peptides represent novel leading compounds for anticancer drug development.
  • Targeting cyclinD/CDK4 complexes with these peptides offers a promising therapeutic strategy for cancer treatment.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...